Arrhythmogenic right ventricular dysplasia endomyocardial biopsy

Jump to navigation Jump to search

Arrhythmogenic right ventricular dysplasia Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Arrhythmogenic right ventricular dysplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X - Ray

ECG

Cardiac MRI

Echocardiogram

Other Imaging Findings

Endomyocardial biopsy

Atuopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Arrhythmogenic right ventricular dysplasia endomyocardial biopsy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Arrhythmogenic right ventricular dysplasia endomyocardial biopsy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Arrhythmogenic right ventricular dysplasia endomyocardial biopsy

CDC on Arrhythmogenic right ventricular dysplasia endomyocardial biopsy

Arrhythmogenic right ventricular dysplasia endomyocardial biopsy in the news

Blogs onArrhythmogenic right ventricular dysplasia endomyocardial biopsy

Directions to Hospitals Treating Arrhythmogenic right ventricular dysplasia

Risk calculators and risk factors for Arrhythmogenic right ventricular dysplasia endomyocardial biopsy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Transvenous biopsy of the right ventricle can be highly specific for ARVD, but it has low sensitivity. False positives include other conditions with fatty infiltration of the ventricle, such as chronic alcohol abuse and Duchenne/Becker muscular dystrophy.

False negatives are common, however, because the disease progresses typically from the epicardium to the endocardium (with the biopsy sample coming from the endocardium), and the segmental nature of the disease. Also, due to the paper-thin right ventricular free wall that is common in this disease process, most biopsy samples are taken from the ventricular septum, which is commonly not involved in the disease process.

A biopsy sample that is consistent with ARVD would have > 3% fat, >40% fibrous tissue, and <45% myocytes.

Endomyocardial biopsy

References